|
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
|
03 April 2017 |
|
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
|
30 January 2017 |
|
Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes
|
09 January 2017 |
|
NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
|
06 December 2016 |
|
Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries
|
14 November 2016 |
|
New study showed that only 55% of people with obesity have received a formal obesity diagnosis
|
03 November 2016 |
|
Novo Nordisk and Aarhus University team up on world-class talents
|
01 July 2016 |
|
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
|
04 April 2016 |
|
Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
|
14 March 2016 |
|
Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
|
10 December 2015 |